Seqirus (part of CSL Limited) was established in 2015 following CSL’s acquisition of the Novartis influenza vaccines and its integration with bioCSL. As the second largest influenza vaccine provider in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Visit seqirus.com.